MedTrace Logo

Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions

NCT06600282 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-09-20

No results posted yet for this study

Summary

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of parecoxib after intravenous bolus of parecoxib in healthy volunteers under fasting conditions

Conditions

  • Post-operative Pain
  • Bioequivalence Study in Healthy Subjects

Interventions

DRUG

Parecoxib

Pharmacokinetic study under fasting conditions

Sponsors & Collaborators

  • Yung Shin Pharm. Ind. Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2024-11-30
Completion
2024-12-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06600282 on ClinicalTrials.gov